J&J Innovation Centers report 12 new partners, investments
This article was originally published in Scrip
Johnson & Johnson's Innovation Centers are living up to their promise of supporting early-stage drug, device and consumer product development with 60 investments or partnerships under their collective belt to date, including 12 recently announced transactions.
You may also be interested in...
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
Reflecting on the latest batch of deals, Global Head Robert Urban discusses the progress J&J Innovation has made so far and the next steps as it launches its JLINX incubator.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.